Inventor
JR., JOHN L. KANE
Inventor
US
Overview
Patents· 6 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations29%
C07DHeterocyclic compounds29%
A61KPreparations for medical, dental or toiletry purposes24%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium14%
C07BGeneral methods of organic chemistry5%
PatentTitleYear
12,503,477Colony stimulating factor-1 receptor (CSF-1R) inhibitors202512,318,392Tropomyosin-related kinase (trk) inhibitors202511,878,024Tropomyosin-related kinase (Trk) inhibitors202411,530,216Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors202211,406,644Tropomyosin-related kinase (TRK) inhibitors202211,274,108Colony stimulating factor-1 receptor (CSF-1R) inhibitors2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2025Patents assigned to GENZYME CORP (6)· patent assignee history
2022–2025Based in US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| GENZYME CORP | 6 | 2022–2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 6 | 2022–2025 |